Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype characterized by a remarkable molecular heterogeneity. Currently, there are no effective druggable targets and advanced preclinical models of human disease. This thesis investigates the role of MYC, a common TNBC deregulated oncogene, in TNBC microenvironment complexities, with a focus on oncogenic transformation of MYC driven therapeutic resistance as well as the functional consequences of targeting MYC in TNBC. Such understanding potentiates a critical need in the field to identify effective targeted therapy for TNBC and establishes a foundation for translating preclinical findings into effective human clinical trials.